New Tenofovir for Hep B Improves Bone and Kidney Safety (CME/CE)
(MedPage Today) -- Formulation now recommended in updated HBV treatment guidelines (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 24, 2017 Category: Gastroenterology Source Type: news
Atripla (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news
Viread (Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news
Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Fixed-dose Combination Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 20, 2017 Category: Drugs & Pharmacology Source Type: news
NHS' anti-HIV drug PrEP approved in Scotland, UK
The Scottish Medicines Consortium (SMC), UK, has approved the supply of Emtricitabine / tenofovir disoproxil (Truvada) by the National Health Service (NHS) to prevent HIV in the nation. (Source: Drug Development Technology)
Source: Drug Development Technology - April 10, 2017 Category: Pharmaceuticals Source Type: news
Vemlidy Tablets (Tenofovir Alafenamide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 10, 2017 Category: Drugs & Pharmacology Source Type: news
New Tenofovir Prodrug Is Noninferior to Currently Used Prodrug New Tenofovir Prodrug Is Noninferior to Currently Used Prodrug
Antiretroviral (ART) combinations containing the recently approved tenofovir alafenamide prodrug offer similar effectiveness and tolerability to those of combinations containing tenofovir disoproxil fumarate, according to two noninferiority trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 10, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Stribild (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 10, 2017 Category: Drugs & Pharmacology Source Type: news
Tenofovir Disoproxil Fumarate Safety for Women and Infants Tenofovir Disoproxil Fumarate Safety for Women and Infants
What does available safety data tell us about preexposure prophylaxis with tenofovir disoproxil fumarate during pregnancy and lactation?AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2017 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news
Europe Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV Europe Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
The efficacy of once-daily Vemlidy is similar to that of tenofovir disoproxil (Viread) with fewer bone and renal side effects, the company says.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 14, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
CDC guidelines for HIV prevention regimen may not go far enough, study suggests
A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.Pre-exposure prophylaxis, or PrEP, is a measure that has proven to be highly effective in preventing HIV transmission during unprotected sex. While not entirely foolproof, studies have shown taking daily doses of tenofovir disoproxil-emtricitabine, or Truvada, is 92 percent effective in preventing HIV infection when taken correctly and consistently.Since 2012, the U.S. Centers fo...
Source: UCLA Newsroom: Health Sciences - January 7, 2017 Category: Universities & Medical Training Source Type: news
ContraVir reports positive Phase IIa trial data of tenofovir exalidex to treat Hepatitis B infection
US-based biopharmaceutical company ContraVir has reported positive data from its ongoing Phase IIa trial of tenofovir exalidex (TXL) to treat Hepatitis B infection. (Source: Drug Development Technology)
Source: Drug Development Technology - December 21, 2016 Category: Pharmaceuticals Source Type: news
Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 20, 2016 Category: Drugs & Pharmacology Source Type: news
HIV prevention trials network launches HPTN 083
(FHI360) The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2016 Category: Global & Universal Source Type: news
The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.
Like tuberculosis and other diseases, drug resistant HIV strains emerge in part because a person doesn’t take the proper dose of drugs at the right time every day. In poor regions like...
Source: Healthy Living - The Huffington Post - December 6, 2016 Category: Consumer Health News Source Type: news
